Stock IPSC CENTURY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Century Therapeutics, Inc.

Equities

IPSC

US15673T1007

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.97 USD -3.57% Intraday chart for Century Therapeutics, Inc. -2.30% -10.54%
May. 10 Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting CI
May. 09 Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting
Century Therapeutics : Corporate Overview May 2024
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Century Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Piper Sandler Adjusts Price Target on Century Therapeutics to $9 From $10, Maintains Overweight Rating
Syncona agrees to sell stake in investee company for GBP7.4 million
Syncona to Sell Stake in Portfolio Company to Century Therapeutics
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Century Therapeutics Announces Plans to Expand Clinical Development for Its Lead Program, CNTY-101
Century Therapeutics, Inc. acquired Clade Therapeutics, Inc. from Syncona Limited for $45 million..
Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors
Century Therapeutics, Inc. agreed to acquire Clade Therapeutics, Inc. from Syncona Limited for $45 million.
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research Annual Meeting
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IPSC Stock
  4. News Century Therapeutics, Inc.
  5. Other languages